315 related articles for article (PubMed ID: 18408759)
1. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
2. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
3. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
4. AID is required for c-myc/IgH chromosome translocations in vivo.
Ramiro AR; Jankovic M; Eisenreich T; Difilippantonio S; Chen-Kiang S; Muramatsu M; Honjo T; Nussenzweig A; Nussenzweig MC
Cell; 2004 Aug; 118(4):431-8. PubMed ID: 15315756
[TBL] [Abstract][Full Text] [Related]
5. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
6. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.
Kotani A; Kakazu N; Tsuruyama T; Okazaki IM; Muramatsu M; Kinoshita K; Nagaoka H; Yabe D; Honjo T
Proc Natl Acad Sci U S A; 2007 Jan; 104(5):1616-20. PubMed ID: 17251349
[TBL] [Abstract][Full Text] [Related]
7. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
[TBL] [Abstract][Full Text] [Related]
8. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
9. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
10. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
11. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
12. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
13. Role of AID in tumorigenesis.
Okazaki IM; Kotani A; Honjo T
Adv Immunol; 2007; 94():245-73. PubMed ID: 17560277
[TBL] [Abstract][Full Text] [Related]
14. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
15. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
Park SS; Shaffer AL; Kim JS; duBois W; Potter M; Staudt LM; Janz S
Cancer Res; 2005 Sep; 65(17):7644-52. PubMed ID: 16140930
[TBL] [Abstract][Full Text] [Related]
16. Constitutive expression of AID leads to tumorigenesis.
Okazaki IM; Hiai H; Kakazu N; Yamada S; Muramatsu M; Kinoshita K; Honjo T
J Exp Med; 2003 May; 197(9):1173-81. PubMed ID: 12732658
[TBL] [Abstract][Full Text] [Related]
17. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
18. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
20. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]